Form 8-K
GILEAD SCIENCES INC filed this Form 8-K on 09/13/2017
Document Outline
Entire Document (1692.9 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01. Entry into a Material Definitive Agreement.
Page 3 - EXHIBIT INDEX
Page 4 - SIGNATURES
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - SCHEDULES
Page 6 - TERM LOAN FACILITY CREDIT AGREEMENT
Page 7 - Acquisition Agreement
Page 8 - Applicable Ticking Fee Rate
Page 9 - Approved Fund
Page 10 - Section 10.06(b)
Page 11 - Borrowing
Page 12 - Clean-up Period
Page 13 - Default Rate
Page 14 - Disqualified Institution
Page 15 - Equity Interests
Page 16 - Eurodollar Base Rate
Page 17 - Section 10.13
Page 18 - Fee Letter
Page 19 - primary obligor
Page 20 - Indemnified Taxes
Page 21 - Laws
Page 22 - Material Subsidiary
Page 23 - Section 10.06
Page 24 - Section 3.06
Page 25 - provided
Page 26 - Master Agreement
Page 27 - Section 2.12
Page 28 - N/A
Page 29 - ARTICLE II
Page 30 - Section 2.02(a)
Page 31 - Sections 8.01(a)
Page 32 - provided
Page 33 - N/A
Page 34 - Section 2.09(a)
Page 35 - Section 2.02
Page 36 - ARTICLE IV
Page 37 - Adjustments
Page 38 - ARTICLE III
Page 39 - N/A
Page 40 - Exhibit E-1
Page 41 - Section 3.01(e)(iv)
Page 42 - Increased Costs Generally
Page 43 - Capital or Liquidity Requirements
Page 44 - Section 10.13
Page 45 - ARTICLE IV
Page 46 - provided
Page 47 - Section 4.02
Page 48 - N/A
Page 49 - N/A
Page 50 - Section 7.01
Page 51 - ARTICLE VI
Page 52 - Sections 6.01(a)
Page 53 - ARTICLE VII
Page 54 - Section 6.04
Page 55 - provided
Page 56 - Section 7.02
Page 57 - Insolvency Proceedings, Etc
Page 58 - Change of Control
Page 59 - Last
Page 60 - provided
Page 61 - ARTICLE IX
Page 62 - Section 10.04
Page 63 - ARTICLE X
Page 64 - provided
Page 65 - Section 10.02(b)
Page 66 - provided
Page 67 - Section 8.02
Page 68 - Section 10.04
Page 69 - Section 10.04(b)
Page 70 - Successors and Assigns Generally
Page 71 - provided
Page 72 - Certain Additional Payments
Page 73 - Participations
Page 74 - Section 3.01(e)
Page 75 - N/A
Page 76 - Section 4.02
Page 77 - Section 3.01
Page 78 - WAIVER OF VENUE
Page 79 - N/A
Page 80 - Judgment Currency
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - SCHEDULE 2.01
Page 96 - SCHEDULE 10.02
Page 97 - EXHIBIT A
Page 98 - N/A
Page 99 - EXHIBIT B
Page 100 - [The remainder of this page intentionally left blank]
Page 101 - N/A
Page 102 - LOANS, CONVERSIONS, CONTINUATIONS AND PAYMENTS
Page 103 - EXHIBIT C
Page 104 - Schedule 2
Page 105 - IN WITNESS WHEREOF,
Page 106 - SCHEDULE 2
Page 107 - EXHIBIT D
Page 108 - identify Lender
Page 109 - Trade Date
Page 110 - N/A
Page 111 - ANNEX 1 TO ASSIGNMENT AND ASSUMPTION
Page 112 - Payments
Page 113 - EXHIBIT E-1
Page 114 - EXHIBIT E-2
Page 115 - EXHIBIT E-3
Page 116 - EXHIBIT E-4
Page 117 - EXHIBIT F
Page 118 - N/A
Page 119 - N/A
Page 120 - N/A
Page 121 - N/A
Page 122 - EXHIBIT G
Page 123 - (iv) the Company does not have unreasonably small capital with which to conduct the businesses in wh
NASDAQ (US Dollar)
$83.27
 Stock is Up 0.65 (0.79%)
Data as of 09/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at Morgan Stanley Global Healthcare Conference

September 11, 2017 9:55 a.m. ET
Play
Gilead Sciences at Citi’s 12th Annual Biotech Conference

September 06, 2017 11:00 a.m. ET
Play
Gilead Sciences Business Update

August 28, 2017 8:00 a.m. ET
Play